$VTRS · Viatris Inc
Viatris reported Q3 FY2026 results: total revenues of $3.749B (flat YoY), adjusted EPS of $0.71 (up 6%), adjusted EBITDA of $1.20B (up 4%), and a U.S. GAAP net loss of $325M versus $128M a year ago, driven by a higher income tax provision. The company raised 2026 guidance midpoints for total revenues ($14.8B), adjusted EBITDA ($4.5B), and adjusted EPS ($2.60). It also announced the planned $1.65B acquisition of Pacira BioSciences, expected to close by end of November.
- Q3 total revenues were $3.749B, flat YoY on reported and operational basis.
- Adjusted EPS of $0.71 rose 6% YoY; GAAP loss per share was $(0.28).
- GAAP net loss widened to $325M from $128M, driven by higher income tax provision.
- 2026 guidance midpoints raised: revenue $14.8B, adjusted EBITDA $4.5B, adjusted EPS $2.60.
- Nashik, India facility suspended manufacturing; ~$100M revenue impact expected in Q4 2026.
Extended-hours last trade $19.28, +0.31% vs regular close and +0.18% vs price-at-filing, a muted reaction to a mixed quarter that beat on adjusted EPS but widened GAAP losses.
A guidance raise and $1.65B M&A pivot toward innovative medicines offset a widening GAAP loss and a manufacturing suspension, leaving a mixed read for investors.
Viatris's pivot toward innovative medicines (Pacira, RYZUMVI, WAKIX) mirrors the broader generics-to-branded shift among pharma peers seeking higher-margin growth.
Nashik, India facility received an Official Action Indicated classification and suspended manufacturing, with ~$100M revenue impact expected in Q4 2026 and production resuming in Q1 2027. Supply constraints in Europe and Emerging Markets continue to pressure generics net sales.